Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 2, 2009, Pages 126-132

  Yamasaki, Daisuke ^a   Nakamura, Tsutomu ^a   Okamura, Noboru ^b   Kokudai, Makiko ^c   Inui, Naoki ^c   Takeuchi, Kazuhiko ^c   Watanabe, Hiroshi ^c   Hirai, Midori ^a   Okumura, Katsuhiko ^a,d   Sakaeda, Toshiyuki ^e  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HIMEJI DOKKYO UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

Constitutive androstane receptor; Inductive effect; P glycoprotein; Pregnane X receptor; Statin; Transcriptional regulation

Indexed keywords

ATORVASTATIN; ATORVASTATIN ACID; ATORVASTATIN LACTONE; CERIVASTATIN; CERIVASTATIN ACID; COUMESTROL; CYTOCHROME P450 3A; FLUINDOSTATIN; FLUVASTATIN ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTONE DERIVATIVE; LOVASTATIN ACID; LOVASTATIN LACTONE; MESSENGER RNA; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; PICROTOXIN; PITAVASTATIN; PITAVASTATIN ACID; PRAVASTATIN ACID; PRAVASTATIN LACTONE; SIMVASTATIN; SIMVASTATIN ACID; SIMVASTATIN LACTONE; SULFORAPHANE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ACIDS; CELL LINE; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 62649141791     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.01.009     Document Type: Article

References (43)

1. Åsberg A., Hartmann A., Fjeldså E., Bergan S., and Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am. J. Transplant. 1 (2001) 382-386
2. Burk O., Arnold K.A., Geick A., Tegude H., and Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol. Chem. 386 (2005) 503-513
3. Chan L.M.S., Lowes S., and Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21 (2004) 25-51
4. Chen C., Mireles R.J., Campbell S.D., Lin J., Mills J.B., Xu J.J., and Smolarek T.A. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33 (2005) 537-546
5. Chung E., Nafziger A.N., Kazierad D.J., and Bertino Jr. J.S. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 79 (2006) 350-361
6. Edwards P.A., Tabor D., Kast H.R., and Venkateswaran A. Regulation of gene expression by SREBP and SCAP. Biochim. Biophys. Acta 1529 (2000) 103-113
7. El-Sankary W., Gibson G.G., Ayrton A., and Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab. Dispos. 29 (2001) 1499-1504
8. Fujino H., Saito T., Tsunenari Y., Kojima J., and Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34 (2004) 961-971
9. Geick A., Eichelbaum M., and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (2001) 14581-14587
10. Gould A.L., Davies G.M., Alemao E., Yin D.D., and Cook J.R. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin. Ther. 29 (2007) 778-794
11. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J., and Kroemer H.K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104 (1999) 147-153
12. Hartley D.P., Dai X., Yabut J., Chu X., Cheng O., Zhang T., He Y.D., Roberts C., Ulrich R., Evers R., and Evans D.C. Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenet. Genomics 16 (2006) 579-599
13. Ishigami M., Honda T., Takasaki W., Ikeda T., Komai T., Ito K., and Sugiyama Y. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab. Dispos. 29 (2001) 282-288
14. Kaneko R., Tsuji N., Asanuma K., Tanabe H., Kobayashi D., and Watanabe N. Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J. Biol. Chem. 282 (2007) 19273-19281
15. Kantola T., Kivistö K.T., and Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 64 (1998) 177-182
16. Kawakami M., Nakamura T., Okamura N., Komoto C., Markova S., Kobayashi H., Hashimoto N., Okumura K., and Sakaeda T. Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells. Biol. Pharm. Bull. 30 (2007) 1065-1073
17. Kobayashi K., Yamanaka Y., Iwazaki N., Nakajo I., Hosokawa M., Negishi M., and Chiba K. Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab. Dispos. 33 (2005) 924-929
18. Kocarek T.A., and Reddy A.B. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab. Dispos. 24 (1996) 1197-1204
19. Kyrklund C., Backman J.T., Kivistö K.T., Neuvonen M., Laitila J., and Neuvonen P.J. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 68 (2000) 592-597
20. Kyrklund C., Backman J.T., Neuvonen M., and Neuvonen P.J. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 57 (2004) 181-187
21. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., and Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102 (1998) 1016-1023
22. Li L., Chen T., Stanton J.D., Sueyoshi T., Negishi M., and Wang H. The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol. Pharmacol. 74 (2008) 443-453
23. Lilja J.J., Kivistö K.T., and Neuvonen P.J. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64 (1998) 477-483
24. Lin J.H., Chiba M., and Baillie T.A. Is the role of the small intestine in first-pass metabolism overemphasized?. Pharmacol. Rev. 51 (1999) 135-158
25. Maglich J.M., Parks D.J., Moore L.B., Collins J.L., Goodwin B., Billin A.N., Stoltz C.A., Kliewer S.A., Lambert M.H., Willson T.M., and Moore J.T. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J. Biol. Chem. 278 (2003) 17277-17283
26. Moriya Y., Nakamura T., Okamura N., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Kasuga M., and Okumura K. Comparison of synthetic DNA templates with authentic cDNA templates in terms of quantification by real-time quantitative reverse transcription polymerase chain reaction. Biol. Pharm. Bull. 29 (2006) 535-538
27. Nakamura T., Sakaeda T., Ohmoto N., Tamura T., Aoyama N., Shirakawa T., Kamigaki T., Nakamura T., Kim K.I., Kim S.R., Kuroda Y., Matsuo M., Kasuga M., and Okumura K. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab. Dispos. 30 (2002) 4-6
28. Neuvonen P.J., Kantola T., and Kivistö K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63 (1998) 332-341
29. Neuvonen P.J., Niemi M., and Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80 (2006) 565-581
30. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., Kapadia S.R., and Nissen S.E. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
31. Oswald S., Haenisch S., Fricke C., Sudhop T., Remmler C., Giessmann T., Jedlitschky G., Adam U., Dazert E., Warzok R., Wacke W., Cascorbi I., Kroemer H.K., Weitschies W., von Bergmann K., and Siegmund W. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin. Pharmacol. Ther. 79 (2006) 206-217
32. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., Cosentino F., Jönsson B., Laakso M., Malmberg K., Priori S., Östergren J., Tuomilehto J., and Thrainsdottir I. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 28 (2007) 88-136
33. Sakaeda T., Fujino H., Komoto C., Kakumoto M., Jin J.S., Iwaki K., Nishiguchi K., Nakamura T., Okamura N., and Okumura K. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm. Res. 23 (2006) 506-512
34. Shitara Y., and Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112 (2006) 71-105
35. Siedlik P.H., Olson S.C., Yang B.B., and Stern R.H. Erythromycin coadministration increases plasma atorvastatin concentrations. J. Clin. Pharmacol. 39 (1999) 501-504
36. Synold T.W., Dussault I., and Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7 (2001) 584-590
37. Ucar M., Neuvonen M., Luurila H., Dahlqvist R., Neuvonen P.J., and Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur. J. Clin. Pharmacol. 59 (2004) 879-882
38. Urquhart B.L., Tirona R.G., and Kim R.B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47 (2007) 566-578
39. Wang E., Casciano C.N., Clement R.P., and Johnson W.W. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res. 18 (2001) 800-806
40. Wang H., Li H., Moore L.B., Johnson M.D., Maglich J.M., Goodwin B., Ittoop O.R.R., Wisely B., Creech K., Parks D.J., Collins J.L., Willson T.M., Kalpana G.V., Venkatesh M., Xie W., Cho S.Y., Roboz J., Redinbo M., Moore J.T., and Mani S. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol. Endocrinol. 22 (2008) 838-857
41. Watanabe H., Kosuge K., Nishio S., Yamada H., Uchida S., Satoh H., Hayashi H., Ishizaki T., and Ohashi K. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci. 76 (2004) 281-292
42. Zhang Y., and Benet L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40 (2001) 159-168
43. Zhou C., Poulton E.J., Grun F., Bammler T.K., Blumberg B., Thummel K.E., and Eaton D.L. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol. Pharmacol. 71 (2007) 220-229